Henry Chow MBChB, FRCSEd (Urol), FCSHK, FHAKM (Surgery), Chi Ho Ip MBBS, FRCSEd (Urol), FCSHK, FHAKM (Surgery), Yiu Chung Lam MBBS, FRCSEd (Urol), FCSHK, FHAKM (Surgery)
{"title":"经尿道水蒸气疗法（Rezūm）治疗继发于良性前列腺增生症的导管依赖型男性：一项针对香港人群的回顾性研究","authors":"Henry Chow MBChB, FRCSEd (Urol), FCSHK, FHAKM (Surgery), Chi Ho Ip MBBS, FRCSEd (Urol), FCSHK, FHAKM (Surgery), Yiu Chung Lam MBBS, FRCSEd (Urol), FCSHK, FHAKM (Surgery)","doi":"10.1111/1744-1633.12689","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>Rezūm is a novel treatment for patients with moderate to severe lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH). Recently, it has expanded to patients with urinary retention causing catheter dependence and the results are promising in Whites. However, it is unclear how effective Rezūm is in the Chinese population. Here, we report our experience in performing Rezūm on catheter-dependent Chinese men with BPH and evaluate its safety and efficacy.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective review of catheter-dependent patients with BPH who underwent Rezūm from January to August 2022 was conducted. We evaluated the success rate of trial without catheter (TWOC) and compared pre- and post-operative (at 6 months) uroflowmetry results, International Prostate Symptoms Score (IPSS), IPSS Quality of Life Score (IPSS QoL), and prostate volume.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Sixty-three patients had Rezūm performed (44 and 19 patients had refractory urinary retention and obstructive uropathy, respectively) with a mean age of 74 years and a mean prostate size of 53.9 mL. The first attempt at TWOC was successful in 53 patients (85.5%; range 15–44 days post-operation). By 98 days after the operation, all patients could void spontaneously. The 6-month follow-up showed that IPSS and IPSS QoL scores decreased by a mean of 9.0 and 1.8 points, respectively (both <i>P</i> < .01). The mean pre-operative post-voided residual urine was reduced by 559 mL (<i>P</i> < .01), with a mean prostate size reduction of 9.4 mL (<i>P</i> < .01). Seven patients had non-serious complications (Grade 1–2 Clavien–Dindo classification) within 30 days of operation.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Rezūm was shown to be effective and safe in catheter-dependent Chinese men with BPH.</p>\n </section>\n </div>","PeriodicalId":51190,"journal":{"name":"Surgical Practice","volume":"28 2","pages":"87-92"},"PeriodicalIF":0.3000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transurethral water vapour therapy (Rezūm) for catheter-dependent men secondary to benign prostatic hyperplasia: A retrospective study in a Hong Kong population\",\"authors\":\"Henry Chow MBChB, FRCSEd (Urol), FCSHK, FHAKM (Surgery), Chi Ho Ip MBBS, FRCSEd (Urol), FCSHK, FHAKM (Surgery), Yiu Chung Lam MBBS, FRCSEd (Urol), FCSHK, FHAKM (Surgery)\",\"doi\":\"10.1111/1744-1633.12689\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>Rezūm is a novel treatment for patients with moderate to severe lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH). Recently, it has expanded to patients with urinary retention causing catheter dependence and the results are promising in Whites. However, it is unclear how effective Rezūm is in the Chinese population. Here, we report our experience in performing Rezūm on catheter-dependent Chinese men with BPH and evaluate its safety and efficacy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A retrospective review of catheter-dependent patients with BPH who underwent Rezūm from January to August 2022 was conducted. We evaluated the success rate of trial without catheter (TWOC) and compared pre- and post-operative (at 6 months) uroflowmetry results, International Prostate Symptoms Score (IPSS), IPSS Quality of Life Score (IPSS QoL), and prostate volume.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Sixty-three patients had Rezūm performed (44 and 19 patients had refractory urinary retention and obstructive uropathy, respectively) with a mean age of 74 years and a mean prostate size of 53.9 mL. The first attempt at TWOC was successful in 53 patients (85.5%; range 15–44 days post-operation). By 98 days after the operation, all patients could void spontaneously. The 6-month follow-up showed that IPSS and IPSS QoL scores decreased by a mean of 9.0 and 1.8 points, respectively (both <i>P</i> < .01). The mean pre-operative post-voided residual urine was reduced by 559 mL (<i>P</i> < .01), with a mean prostate size reduction of 9.4 mL (<i>P</i> < .01). Seven patients had non-serious complications (Grade 1–2 Clavien–Dindo classification) within 30 days of operation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Rezūm was shown to be effective and safe in catheter-dependent Chinese men with BPH.</p>\\n </section>\\n </div>\",\"PeriodicalId\":51190,\"journal\":{\"name\":\"Surgical Practice\",\"volume\":\"28 2\",\"pages\":\"87-92\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2024-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/1744-1633.12689\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1744-1633.12689","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
Transurethral water vapour therapy (Rezūm) for catheter-dependent men secondary to benign prostatic hyperplasia: A retrospective study in a Hong Kong population
Aim
Rezūm is a novel treatment for patients with moderate to severe lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH). Recently, it has expanded to patients with urinary retention causing catheter dependence and the results are promising in Whites. However, it is unclear how effective Rezūm is in the Chinese population. Here, we report our experience in performing Rezūm on catheter-dependent Chinese men with BPH and evaluate its safety and efficacy.
Methods
A retrospective review of catheter-dependent patients with BPH who underwent Rezūm from January to August 2022 was conducted. We evaluated the success rate of trial without catheter (TWOC) and compared pre- and post-operative (at 6 months) uroflowmetry results, International Prostate Symptoms Score (IPSS), IPSS Quality of Life Score (IPSS QoL), and prostate volume.
Results
Sixty-three patients had Rezūm performed (44 and 19 patients had refractory urinary retention and obstructive uropathy, respectively) with a mean age of 74 years and a mean prostate size of 53.9 mL. The first attempt at TWOC was successful in 53 patients (85.5%; range 15–44 days post-operation). By 98 days after the operation, all patients could void spontaneously. The 6-month follow-up showed that IPSS and IPSS QoL scores decreased by a mean of 9.0 and 1.8 points, respectively (both P < .01). The mean pre-operative post-voided residual urine was reduced by 559 mL (P < .01), with a mean prostate size reduction of 9.4 mL (P < .01). Seven patients had non-serious complications (Grade 1–2 Clavien–Dindo classification) within 30 days of operation.
Conclusion
Rezūm was shown to be effective and safe in catheter-dependent Chinese men with BPH.
期刊介绍：
Surgical Practice is a peer-reviewed quarterly journal, which is dedicated to the art and science of advances in clinical practice and research in surgery. Surgical Practice publishes papers in all fields of surgery and surgery-related disciplines. It consists of sections of history, leading articles, reviews, original papers, discussion papers, education, case reports, short notes on surgical techniques and letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
